Drug Trial Radar · NCT01147250
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Last checked: Nov 20, 2026Latest source record: Dec 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,068
Actual
Start
Jun 2010
Primary completion
Feb 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: \- To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina) compared to placebo in type 2 diabetic participants who recently experienced an acute coronary syndrome (ACS) event. Secondary Objectives: To demonstrate that when compared to placebo, lixisenatide can reduce: * composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, or hospitalization for heart failure. * composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, or coronary revascularization procedure. * urinary albumin excretion (based on the urinary albumin/creatinine ratio). To assess the safety and tolerability of lixisenatide.
Conditions
- Acute Coronary Syndrome
Interventions
Lixisenatide (AVE0010)Drug
Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
PlaceboDrug
Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable AnginaTime frame: From randomization up to the end of study (median follow-up of 25 months)
Locations
829 sites in 49 countries. Site status is shown where the registry gives one.
Investigational Site Number 840415
Birmingham, Alabama
Investigational Site Number 840307
Foley, Alabama
Investigational Site Number 840692
Mobile, Alabama
Investigational Site Number 840037
Mobile, Alabama
Investigational Site Number 840210
Mobile, Alabama
Investigational Site Number 840326
Muscle Shoals, Alabama
Investigational Site Number 840393
Toney, Alabama
Investigational Site Number 840656
Mesa, Arizona
Investigational Site Number 840506
Phoenix, Arizona
Investigational Site Number 840520
Phoenix, Arizona
Investigational Site Number 840322
Phoenix, Arizona
Investigational Site Number 840250
Tempe, Arizona
Investigational Site Number 840042
Tucson, Arizona
Investigational Site Number 840303
Hot Springs, Arkansas
Investigational Site Number 840184
Jonesboro, Arkansas
Investigational Site Number 840361
Little Rock, Arkansas
Investigational Site Number 840023
Little Rock, Arkansas
Investigational Site Number 840706
Anaheim, California
Investigational Site Number 840497
Anaheim, California
Investigational Site Number 840667
Downey, California
Investigational Site Number 840150
Fresno, California
Investigational Site Number 840624
Hawthorne, California
Investigational Site Number 840623
Inglewood, California
Investigational Site Number 840636
Inglewood, California
Investigational Site Number 840455
La Mesa, California
Investigational Site Number 840240
Loma Linda, California
Investigational Site Number 840262
Long Beach, California
Investigational Site Number 840606
Long Beach, California
Investigational Site Number 840694
Los Angeles, California
Investigational Site Number 840431
Los Angeles, California
Investigational Site Number 840135
Los Angeles, California
Investigational Site Number 840314
Merced, California
Investigational Site Number 840290
Mission Viejo, California
Investigational Site Number 840592
National City, California
Investigational Site Number 840275
Northridge, California
Investigational Site Number 840654
Oakland, California
Investigational Site Number 840351
Orange, California
Investigational Site Number 840689
Orange, California
Investigational Site Number 840582
Pomona, California
Investigational Site Number 840346
Port Hueneme, California
Showing 40 of 829 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.